Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory ...

A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS ...

Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., have described a next-generation vaccination technology ...

NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

Discover Lantern Pharma's transformative 2024 journey in precision oncology with AI breakthroughs, global trial expansions, and key clinical milestones ...

Long-term treatment with Duvyzat (givinostat) may help delay the loss of walking ability and lessen the decline in lung ...

HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCCUpdated data from ongoing Phase 1/1b trial in 1L ...

AMVETS Scholarships: AMVETS scholarships are designed to fulfill a financial gap after all Federal/State grants and/or scholarships available to an eligible Veteran, Active Duty, Guard and Reserve; ...

Neurosense reports Canadian regulators want a meeting that could lead to PrimeC's conditional approval there, and further ...

The global Central Lab Services Market, valued at US$5.64 billion in 2024, is forecasted to grow at a robust CAGR of 6.5%, ...

Use of DYNE-101 is leading to improvements in muscle, and specifically finger, function in myotonic dystrophy type 1 patients ...

The UK paved the way for global vaccine development during the Covid pandemic, with the Oxford-AstraZeneca vaccine – a collaboration between researchers at the University of Oxford and the ...